HI
KRYS icon

Harbour Investments’s Krystal Biotech KRYS Stock Holding History

Harbour Investments’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5K Buy
39
+6
+18% +$1.79K ﹤0.01% 3144
2026
Q1 		$8.53K Hold
33
– – ﹤0.01% 3346
2025
Q4 		$8.14K Buy
+33
New +$6.95K ﹤0.01% 2836
2025
Q1 		– Sell
-14
Closed -$2.19K – 3612
2024
Q4 		$2.19K Buy
+14
New +$2.48K ﹤0.01% 2992

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Harbour Investments's KRYS Position: Q2 2026 in Review

Harbour Investments increased its Krystal Biotech (KRYS) stake by 18% in Q2 2026, buying an estimated $1.79K and bringing the position to 39 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3144.

Harbour Investments first reported a position in KRYS in Q4 2024 and has held it in 4 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Harbour Investments held 39 shares of Krystal Biotech worth $14.5K as of Q2 2026.
  • Harbour Investments bought 6 Krystal Biotech shares in Q2 2026, an estimated $1.79K.
  • Krystal Biotech made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #3144 holding.
  • Harbour Investments first reported a position in Krystal Biotech in Q4 2024 and has held it in 4 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.